AAMU
BSTC

Amundi Asset Management US’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Amundi Asset Management US’s Portfolio BSTC Stock Details BSTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,300
Closed -$135K – 1701
2018
Q3 		$135K Buy
+2,300
New +$117K ﹤0.01% 1495

Other funds holding BSTC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Amundi Asset Management US's BSTC Position: Q4 2018 in Review

Amundi Asset Management US sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2018, closing a stake of 2,300 shares — an estimated $135K sold.

Amundi Asset Management US first reported a position in BSTC in Q3 2018 and held it in 1 quarter. The position peaked at $135K in Q3 2018. 107 funds tracked by Wall St. Rank hold BSTC as of Q4 2018.

  • Amundi Asset Management US reported no remaining BioSpecifics Technologies Corp. position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 2,300 BioSpecifics Technologies Corp. shares in Q4 2018, an estimated $135K.
  • Amundi Asset Management US first reported a position in BioSpecifics Technologies Corp. in Q3 2018 and held it in 1 quarter.
  • Amundi Asset Management US's BioSpecifics Technologies Corp. position peaked at $135K in Q3 2018.
  • 107 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.